Top 10 Companies in the (S)-1-(2,6-Dichloro-3-Fluorophenyl)Ethanol Market (2026): Market Leaders Powering Specialty Chiral Chemistry

MARKET INSIGHTS

Global (S)-1-(2,6-Dichloro-3-Fluorophenyl)Ethanol market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.6 million in 2026 to USD 54.8 million by 2034, exhibiting a CAGR of 6.7% during the forecast period.

(S)-1-(2,6-Dichloro-3-Fluorophenyl)Ethanol is a chiral alcohol compound characterized by a phenylethanol backbone bearing two chlorine substituents at the 2- and 6-positions and a fluorine atom at the 3-position of the aromatic ring. This enantiomerically pure intermediate holds significant importance in pharmaceutical synthesis, particularly as a key building block in the manufacturing of roflumilast, a selective phosphodiesterase-4 (PDE4) inhibitor used in the treatment of chronic obstructive pulmonary disease (COPD).

The market is witnessing steady growth driven by rising global demand for specialty pharmaceutical intermediates and the expanding pipeline of fluorinated and halogenated active pharmaceutical ingredients (APIs). Furthermore, the growing emphasis on asymmetric synthesis and chiral chemistry in drug development continues to reinforce demand for high-purity enantiomeric compounds. Leading fine chemical and pharmaceutical ingredient manufacturers, including Asymchem Laboratories, Hikal Ltd., and Zhejiang Langhua Pharma, are among the key suppliers actively catering to this niche yet strategically important segment.

(S)-1-(2,6-Dichloro-3-Fluorophenyl)Ethanol Market – View in Detailed Research Report

🔟 1. Shanghai Sinofluoro Chemicals Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Fluorinated chiral intermediates for API development

Shanghai Sinofluoro has established a robust production line for high‑purity (S)-1-(2,6‑Dichloro‑3‑Fluorophenyl)Ethanol, leveraging advanced asymmetric catalysis and stringent GMP processes to meet the exacting standards of global pharmaceutical clients.

Sustainability & Growth Initiatives:

• Investment in low‑energy catalytic processes to reduce carbon footprint
• Partnerships with academic institutions to develop greener biocatalytic routes
• Expansion of regional distribution hubs in Asia‑Pacific to improve supply chain resilience

9️⃣ 2. PharmaBlock Sciences (Nanjing), Inc.

Headquarters: Nanjing, China
Key Offering: Comprehensive chiral building block catalog for drug discovery

PharmaBlock provides a broad range of chiral intermediates, including (S)-1-(2,6‑Dichloro‑3‑Fluorophenyl)Ethanol, with rapid turnaround times and detailed analytical data to support early‑stage R&D.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop solvent recovery systems
• Certification of ISO 9001 and ISO 14001 for quality and environmental management
• Strategic collaborations with leading CROs for co‑development projects

8️⃣ 3. Jiangsu Aikon Biopharmaceutical R&D Co., Ltd.

Headquarters: Jiangsu, China
Key Offering: Pharmaceutical‑grade chiral alcohols for API synthesis

Aikon specializes in scalable, GMP‑compliant production of (S)-1‑(2,6‑Dichloro‑3‑Fluorophenyl)Ethanol, enabling rapid supply for oncology and anti‑inflammatory drug programs.

Sustainability & Growth Initiatives:

• Adoption of renewable energy sources for manufacturing facilities
• Research into biocatalytic reduction using engineered ketoreductases
• Expansion of contract manufacturing services for global biopharma partners

7️⃣ 4. Fluorochem Ltd.

Headquarters: London, United Kingdom
Key Offering: Specialty fluorinated intermediates for pharmaceuticals and agrochemicals

Fluorochem’s UK‑based operations deliver high‑purity (S)-1‑(2,6‑Dichloro‑3‑Fluorophenyl)Ethanol with robust safety data and regulatory support for European markets.

Sustainability & Growth Initiatives:

• Carbon‑neutral production targets by 2030
• Development of eco‑friendly solvent systems
• Partnerships with EU research consortia for advanced chiral synthesis

6️⃣ 5. Oakwood Chemical

Headquarters: Chicago, United States
Key Offering: Bulk supply of chiral intermediates for API manufacturing

Oakwood offers large‑scale production of (S)-1‑(2,6‑Dichloro‑3‑Fluorophenyl)Ethanol, supporting major pharmaceutical manufacturers with consistent quality and fast lead times.

Sustainability & Growth Initiatives:

• Implementation of waste‑heat recovery systems
• Compliance with US EPA and OSHA safety regulations
• Expansion of on‑demand synthesis capabilities for niche projects

5️⃣ 6. Combi-Blocks, Inc.

Headquarters: San Diego, United States
Key Offering: Custom synthesis of chiral building blocks for drug discovery

Combi-Blocks provides tailored synthesis of (S)-1‑(2,6‑Dichloro‑3‑Fluorophenyl)Ethanol with rapid scale‑up for academic and industrial R&D.

Sustainability & Growth Initiatives:

• Adoption of green chemistry principles in all processes
• Use of renewable feedstocks where possible
• Strategic alliances with biotech incubators for early‑stage projects

4️⃣ 7. AK Scientific, Inc.

Headquarters: Houston, United States
Key Offering: High‑purity chiral reagents for pharmaceutical synthesis

AK Scientific delivers (S)-1‑(2,6‑Dichloro‑3‑Fluorophenyl)Ethanol with rigorous analytical data, supporting both small‑batch and commercial production.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop solvent recycling
• Investment in continuous flow chemistry platforms
• Collaboration with global CROs to streamline supply chains

3️⃣ 8. Nanjing Chemlin Chemical Industry Co., Ltd.

Headquarters: Nanjing, China
Key Offering: Fluorinated chiral intermediates for API and agrochemical applications

Chemlin’s production focuses on high‑purity (S)-1‑(2,6‑Dichloro‑3‑Fluorophenyl)Ethanol, supporting both domestic and international pharmaceutical projects.

Sustainability & Growth Initiatives:

• Adoption of energy‑efficient catalytic processes
• Partnerships with research institutes for new synthetic routes
• Expansion of GMP‑certified production lines

2️⃣ 9. Wuhan Fortuna Chemical Co., Ltd.

Headquarters: Wuhan, China
Key Offering: Specialty chiral chemicals for pharmaceutical synthesis

Fortuna specializes in scalable production of (S)-1‑(2,6‑Dichloro‑3‑Fluorophenyl)Ethanol, with a focus on meeting stringent regulatory requirements.

Sustainability & Growth Initiatives:

• Implementation of green solvent systems
• Development of biocatalytic routes for chiral reduction
• Expansion of on‑demand synthesis services for niche markets

1️⃣ 10. Asymchem Laboratories

Headquarters: Bengaluru, India
Key Offering: Enantiomerically pure intermediates for drug development

Asymchem provides high‑purity (S)-1‑(2,6‑Dichloro‑3‑Fluorophenyl)Ethanol with comprehensive analytical support, enabling rapid progression of drug candidates through clinical pipelines.

Sustainability & Growth Initiatives:

• Investment in renewable energy for manufacturing facilities
• Research into enzyme‑based asymmetric synthesis
• Strategic collaborations with Indian pharma to expand market reach

(S)-1-(2,6-Dichloro-3-Fluorophenyl)Ethanol Market – View in Detailed Research Report

(S)-1-(2,6-Dichloro-3-Fluorophenyl)Ethanol Market – View in Detailed Research Report

Market Outlook

The (S)-1-(2,6‑Dichloro‑3‑Fluorophenyl)Ethanol market is set to experience steady growth, driven by expanding pipelines of kinase inhibitors and precision oncology therapies. The increasing emphasis on chiral purity and the adoption of biocatalytic processes are expected to lower production costs and enhance supply chain resilience. With the Asia‑Pacific region emerging as a key manufacturing hub, global demand is projected to rise, supported by robust R&D activities and regulatory alignment with ICH guidelines.

Future Trends

Key trends include the integration of engineered ketoreductases for scalable biocatalytic production, the expansion of on‑demand synthesis platforms, and the growing focus on sustainability through green chemistry practices. Additionally, the shift toward single‑enantiomer drug candidates will further elevate the premium positioning of high‑purity (S)-1‑(2,6‑Dichloro‑3‑Fluorophenyl)Ethanol, driving long‑term demand across pharmaceutical and agrochemical sectors.